Search the Newsreel

Ncino chief legal & admin ofc. April Rieger sells $150,899 in stock

April Rieger, Chief Legal & Administrative Officer of nCino, sold 7,852 shares of common stock totaling $150,899 to cover tax withholding obligations. This transaction was not a discretionary trade but mandated by the company's equity incentive plans. Despite the sale, nCino shares are down …

Hua Medicine Issues Profit Warning as One-Off Bayer Gain Drops Out

Ncino SVP of accounting Jeanette Sellers sells $47,044 in shares By Investing.com

Jeanette Sellers, SVP of Accounting at nCino, Inc. (NASDAQ:NCNO), sold shares totaling $47,044 in two separate transactions. The sales were primarily to cover tax obligations from restricted stock units and executed under a pre-arranged trading plan. Despite the insider sale, nCino's stock is considered …

nCino (NCNO) CEO exercises options and sells 40,490 shares under plans

nCino, Inc. CEO Sean Desmond exercised stock options for 8,064 shares and subsequently sold a total of 40,490 shares of common stock on August 4 and 5, 2026. The sales were conducted at prices of $19.218 and $19.53, with a significant portion (28,675 shares) …

nCino (NCNO) director sells 4,677 shares to cover RSU tax withholding

nCino, Inc. director Naude Pierre sold 4,677 shares of common stock on August 4, 2026, at $19.218 per share. This sale was a non-discretionary transaction to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). Following this transaction, Naude Pierre …

Ncino CEO Sean Desmond sells $781,823 in shares

nCino, Inc. CEO Sean Desmond recently sold shares totaling $781,823 in early August. These sales included shares to cover tax withholding obligations and others executed under a Rule 10b5-1 trading plan. Despite the sales, Desmond retains significant ownership, and analysts predict profitability for nCino …

nCino (NCNO) SVP reports 2,423-share sales for tax and 10b5-1 plan

nCino's SVP of Accounting, Jeanette Sellers, reported selling a total of 2,423 shares of common stock. A portion of these shares (887) were sold on August 4, 2026, to cover tax withholding on RSU vesting, which was a mandatory sale. The remaining 1,536 shares …

nCino (NCNO) officer sells 7,852 shares to cover RSU tax obligations

April Rieger, Chief Legal & Administrative Officer and Secretary of nCino, Inc. (NCNO), sold 7,852 shares of common stock on August 4, 2026, at $19.218 per share. This transaction was non-discretionary and executed to cover tax withholding obligations upon the vesting of Restricted Stock …

IRON (IRON) filer plans 5,000-share stock sale after option exercise

An IRON insider has filed a Form 144 notice to sell 5,000 shares of common stock, valued at $394,550.00, on August 6, 2026. This sale follows the exercise of stock options for cash on the same date. The filing also details previous Rule 10b5-1 …

Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside

Revolution Medicines, Inc. (RVMD) has seen its average price target raised from $207.16 to $216.4 by 20 analysts, with forecasts ranging from $151 to $263 per share. This updated target suggests a potential 10% upside based on the Aug. 5 closing price. The consensus …

Praxis Precision Medicines (NASDAQ: PRAX) holds $1.4B cash, advances NDAs

Praxis Precision Medicines reported a Q2 2026 net loss of $83.7 million and a first-half loss of $176.3 million, driven by increased R&D and G&A expenses to fund clinical programs and commercial preparation. Despite these losses, the company holds $1.4 billion in cash, cash …

Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash

Generate Biomedicines reported its second-quarter 2026 results, showing $6.3 million in collaboration revenue and a net loss of $67.3 million. The company held $457.4 million in cash, which is expected to fund operations into the first half of 2028, and highlighted advancement in multiple …

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

Revolution Medicines RVMD reported an adjusted loss of $2.34 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.93. The adjusted figure excluded a non-cash charge of $151 million tied to a change in the …

Prime Medicine, Inc. (PRME) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Prime Medicine, Inc. (PRME), including its current stock price, trading activity, historical data, and company overview. It highlights key financial metrics, recent news, performance comparisons against the S&P 500, and analyst ratings, alongside details of its …

H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Announces Target Price $120

H.C. Wainwright has reiterated its Buy rating on Disc Medicine (IRON.US) and set a target price of $120. This indicates a strong positive outlook from the firm regarding the company's stock performance.

Praxis Precision Medicines gains as investors refocus on late-stage CNS pipeline and upcoming FDA catalysts

FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS)

FMR LLC has filed a Schedule 13G, disclosing a passive ownership stake of 10,292,735 shares, representing 8.5% of Parabilis Medicines Inc.'s outstanding common stock. Both FMR LLC and Abigail P. Johnson, a reporting person, hold sole dispositive power over these shares, with FMR LLC …

Cincinnati Financial (CINF) files Form 13F showing $5.23B across 56 positions

Cincinnati Financial Corp (CINF) has filed a Form 13F-HR, disclosing 56 portfolio positions with a total value of $5.23 billion. The filing, signed by Chief Investment Officer Steven A. Soloria, is a combination report, indicating that some holdings are reported by CINF directly while …

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and …

Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary

Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate …

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Better-Than-Expected Earnings

Disc Medicine (IRON): FMR LLC, Abigail Johnson report 12.8% ownership of common stock

FMR LLC and Abigail P. Johnson have reported an updated beneficial ownership of 12.8% of Disc Medicine Inc. (IRON) common stock, totaling 4,875,472.97 shares, through an Amendment No. 4 to a Schedule 13G filing. FMR LLC holds sole voting power over 4,875,263 shares and …

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) reported a Q2 loss of $0.24 per share, aligning with Zacks Consensus Estimate but missing revenue estimates significantly at $1.15 million. The company has consistently missed revenue expectations over the last four quarters, and its shares have underperformed the S&P …

Praxis Precision Medicines stock hits 52-week high at 366.7 USD

Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, reflecting a 557% one-year return and a market cap of $9.92 billion, despite an InvestingPro analysis suggesting it may be overvalued. The company recently reported a Q2 2026 loss of $2.87 …

Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss

HC Wainwright Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

HC Wainwright has increased its price target for Disc Medicine (NASDAQ:IRON) to $120 from $118, maintaining a "Buy" rating and suggesting a 52% upside. Analyst sentiment is generally positive, with a consensus "Moderate Buy" rating and an average target of $106. Despite beating quarterly …

Generate Biomedicines Shares Fall Following Q2 Financial Results

Generate Biomedicines (GENB) shares dropped by 4.6% after the company announced its Q2 financial results, indicating a wider loss than expected. The full details of the financial performance are behind a premium paywall.

Praxis Precision Medicines beats Q2 loss estimates; shares rise

Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported a Q2 loss of $2.87 per share, outperforming analyst estimates. The company's shares rose 6.5% in premarket trading following the news, which also highlighted progress with FDA interactions for its drug candidates ulixacaltamide HCl and relutrigine, and a …

Sei Investments Co. Buys 86,585 Shares of Cinemark Holdings Inc $CNK

Sei Investments Co. significantly increased its stake in Cinemark Holdings Inc (CNK) by 113.9% in the first quarter, now owning 162,635 shares valued at approximately $4.64 million. Several other institutional investors also increased their positions. Analysts maintain a "Moderate Buy" rating for Cinemark, with …

Here's How Much a $1000 Investment in Cintas Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in …

FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME)

Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine has reported its second-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing a global Phase 1/2 program, and an arbitration resolution affirmed its rights to PM647 for …

Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO

Janus Henderson Group PLC Purchases 8,623 Shares of Cintas Corporation $CTAS

Janus Henderson Group PLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 20% in the first quarter, acquiring an additional 8,623 shares, bringing their total holdings to 51,716 shares valued at $8.75 million. Cintas has consistently exceeded quarterly expectations, reporting strong revenue growth and …

Pacer Advisors Inc. Lowers Stake in Cintas Corporation $CTAS

Pacer Advisors Inc. significantly reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 34.8% in the first quarter, selling over 21,000 shares. Despite this, Cintas continues to exceed earnings expectations, reporting $1.29 EPS and $2.91 billion in revenue, and has increased its quarterly dividend. The …